However, RUNX3 was not added into the DEABM based on its known tumor suppressor capability, rather it was chosen for its effect on suppressing the proliferative potential of ER+ cells, a functional capability that needed to be added to the earlier version of the DEABM. Here, ESR1 is linked to neoplasm.